×
About 388 results

ALLMedicine™ Erythroleukemia Center

Research & Reviews  153 results

EloA promotes HEL polyploidization upon PMA stimulation through enhanced ERK1/2 activity.
https://doi.org/10.1080/09537104.2021.1988548
Platelets Hu L, Zhang W et. al.

Oct 27th, 2021 - Megakaryocytes (MKs) are the unique non-pathological cells that undergo polyploidization in mammals. The polyploid formation is critical for understanding the MK biology, and transcriptional regulation is involved in the differentiation and matura...

Involvement of autophagy in diosgenin‑induced megakaryocyte differentiation in human er...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8436216
Molecular Medicine Reports; Diab D, Pinon A et. al.

Aug 31st, 2021 - Natural agents have been used to restart the process of differentiation that is inhibited during leukemic transformation of hematopoietic stem or progenitor cells. Autophagy is a housekeeping pathway that maintains cell homeostasis against stress ...

BET inhibitors enhance embryonic and fetal globin expression in erythroleukemia cell li...
https://doi.org/10.3324/haematol.2021.278791
Haematologica Cao JZ, Bigelow K et. al.

Aug 27th, 2021 - BET inhibitors enhance embryonic and fetal globin expression in erythroleukemia cell lines.|2021|Cao JZ,Bigelow K,Wickrema A,Godley LA,|

Cabozantinib promotes erythroid differentiation in K562 erythroleukemia cells through g...
https://doi.org/10.1038/s41417-021-00358-w 10.1016/j.cell.2016.08.057 10.1038/nm.3995 10.1182/blood-2011-12-399667 10.1182/blood-2013-03-488114 10.1126/science.1234769 10.1182/blood-2017-04-779447 10.1128/MCB.17.4.1947 10.1096/fasebj.12.7.531 10.1074/jbc.M008092200 10.1016/j.exphem.2018.02.007 10.1158/1535-7163.MCT-11-0264 10.2217/fon.13.128 10.1080/14737140.2017.1344553 10.1007/s11864-018-0517-1 10.1056/NEJMoa1717002 10.1016/j.canlet.2016.04.004 10.1002/cncr.31038 10.1200/JCO.2010.32.4145 10.1074/jbc.M602712200 10.1038/leu.2009.69 10.1158/2159-8290.CD-15-0060 10.1128/MCB.25.4.1215-1227.2005 10.1182/blood.V96.8.2641 10.1182/blood-2011-03-343475 10.1038/nature13614 10.3390/ijms21155577 10.3324/haematol.2018.210054 10.1096/fj.201902946R 10.1038/sj.onc.1210034 10.1016/S0014-5793(01)02810-1 10.1182/blood.V92.6.1859 10.1371/journal.pone.0023720 10.1182/blood.V94.3.853.415a12_853_863 10.1182/blood.V95.7.2391 10.1002/ajh.10245 10.1002/jcp.10426 10.1074/jbc.M007291200 10.1038/onc.2012.246 10.1074/jbc.M500758200 10.3389/fgene.2020.00019 10.1007/s11427-015-4967-4 10.1093/nar/gkz114 10.1093/bioinformatics/btt087 10.1038/nprot.2008.211 10.1073/pnas.0506580102
Cancer Gene Therapy; Fu YH, Ou DL et. al.

Jun 13th, 2021 - Cabozantinib is a potent tyrosine kinase inhibitor with multiple targets including MET, VEGFR2, RET, KIT, and FLT3. Cabozantinib is widely used for the treatment of medullary thyroid cancer and renal cell carcinoma. We recently suggested cabozanti...

ERK activation via A1542/3 limonoids attenuates erythroleukemia through transcriptional...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8191108
BMC Cancer; Yu F, Gajendran B et. al.

Jun 11th, 2021 - Cholesterol plays vital roles in human physiology; abnormal levels have deleterious pathological consequences. In cancer, elevated or reduced expression of cholesterol biosynthesis is associated with good or poor prognosis, but the underlying mech...

see more →

Clinicaltrials.gov  1 results

Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or Mediastinum
https://clinicaltrials.gov/ct2/show/NCT01313429

Mar 3rd, 2020 - Background: During recent years, the cancer-testis (CT) antigens (CTA) have emerged as attractive targets for cancer immunotherapy. Whereas malignancies of diverse histologies express a variety of CTAs, immune responses to these antigens appear un...

see more →

News  1 results

Inhibitor exhibits activity against hematologic malignancies
https://www.mdedge.com/hematology-oncology/article/185742/leukemia-myelodysplasia-transplantation/inhibitor-exhibits
HT Staff

Apr 18th, 2017 - Photo by Rhoda Baer Researchers in the lab A dual kinase inhibitor is active against a range of hematologic malignancies, according to preclinical research. Investigators found that ASN002, a SYK/JAK inhibitor, exhibited “potent” antiproliferative.

see more →